AsianScientist (Jul. 6, 2016) – Pfizer Inc. has announced an investment of approximately US$350 million in a Global Biotechnology Center in the Hangzhou Economic Development Area in China.
This facility, which is expected to be completed in 2018, will be Pfizer’s third biotechnology center globally and the first in Asia.
It will house Pfizer China’s Biosimilars and Biologics Quality, Technical Service, Logistics and Engineering divisions, in addition to commercial manufacturing, and will also serve as a process development and clinical supply site. It will also include an advanced modular facility by GE Healthcare.
The Hangzhou unit will ensure the local production of high-quality, affordable biosimilar medicines for both the Chinese and international markets. It represents Pfizer’s further investment in R&D and clinical research across China, and will create more than 150 job opportunities locally.
———
Source: Pfizer.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
